N-carbomethoxy-2,5-dimethylpyrrole | 5044-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: N-carbomethoxy-2,5-dimethylpyrrole
• 英文别名: N-methoxycarbonyl-2,5-dimethyl pyrrole；2,5-dimethylpyrrole-1-carboxylic acid methyl ester；2,5-Dimethyl-1-methoxycarbonyl-pyrrol；1-Carbomethoxy-2,5-dimethylpyrrol；Methyl-2,5-dimethylpyrrol-1-carboxylat；1-Methoxycarbonyl-2,5-dimethyl-pyrrol；2,5-dimethyl-N-carbomethoxypyrrole；Methyl 2,5-dimethyl-1H-pyrrole-1-carboxylate；methyl 2,5-dimethylpyrrole-1-carboxylate
• CAS: 5044-30-4
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: YRTOCIAZPCWZPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N-carbomethoxy-2,5-dimethylpyrrole 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 三甲基氯硅烷 、 diethylzinc 、 potassium acetate 、 potassium carbonate 、 氯化铵 、 三苯基膦 、 锌 、 lithium diisopropyl amide 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成
  参考文献：
  名称：

  WO2020163405A5

  摘要：

  公开号：

  WO2020163405A5
• 作为产物：
  描述：

  在 对甲苯磺酸 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 N-carbomethoxy-2,5-dimethylpyrrole
  参考文献：
  名称：

  由N保护的琥珀酰亚胺方便地一锅合成多取代的吡咯

  摘要：

  由多取代的琥珀酰亚胺与Petasis试剂之间的反应形成的二烯胺产物在温和的酸性条件下进行异构化，以优异的收率（85-95％）得到多取代的吡咯。探索了这种方法的范围和局限性。

  DOI：

  10.1016/j.tetlet.2014.03.021

文献信息

• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20090105296A1

  公开（公告）日：2009-04-23

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  该发明涉及以下式I的化合物： 其中Z、X、J、R2和W如规范中所述，以及其溶剂化合物、水合物、互变异构体和药学上可接受的盐，能够抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了治疗自身免疫疾病；以及伴有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经源性疼痛；以及骨质疏松症、帕盖特病和其他骨吸收介导发病率的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失败、溶骨性肉瘤、骨髓瘤和肿瘤转移至骨骼的方法，其中使用了式I的化合物。
• 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic
  申请人：UCB S.A. - DTB

  公开号：US06060473A1

  公开（公告）日：2000-05-09

  7-Azabicyclo[2.2.1]-heptane and -heptene derivatives are disclosed that can be administered to a mammal, including a human, to treat disorders associated with a decrease or increase in cholinergic activity.

  揭示了可以用于治疗与胆碱能活性降低或增加相关的疾病的7-Azabicyclo[2.2.1]-heptane和-heptene衍生物，可用于给哺乳动物，包括人类。
• 7-Azabicyclo\x9b2.2.1!-heptane and -heptene derivatives as cholinergic
  申请人：University of Virginia

  公开号：US05817679A1

  公开（公告）日：1998-10-06

  7-Aza-bicyclo\x9b2.2.1!-heptane and -heptene derivatives are disclosed that can be administered to a mammal, including a human, to treat disorders associated with a decrease or increase in cholinergic activity.

  披露了可以用于治疗与胆碱能活性增减有关的疾病的7-Aza-bicyclo\x9b2.2.1！-庚烷和-庚烯衍生物，可用于给哺乳动物，包括人类。
• Inhibitors of c-fms kinase
  申请人：Illig Carl R.

  公开号：US08497376B2

  公开（公告）日：2013-07-30

  The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及式I的化合物：其中Z、X、J、R2和W在规范中列出，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，其抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或脏器、炎症和神经源性疼痛；以及骨质疏松症、帕吉特病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失效、骨溶解性肉瘤、骨髓瘤和转移至骨骼的肿瘤。
• [EN] 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS<br/>[FR] DERIVES DE 7-AZABICYCLO[2.2.1]-HEPTANE et -HEPTENE UTILISES COMME ANALGESIQUES ET AGENTS ANTI-INFLAMMATOIRES
  申请人：UNIVERSITY OF VIRGINIA

  公开号：WO1994022868A1

  公开（公告）日：1994-10-13

  (EN) 7-Azabicyclo[2.2.1]-heptane and -heptene derivatives with analgesic or anti-inflammatory activity are disclosed that can be administered to a mammal, including a human, to treat pain and inflammatory disorders. A method for the treatment of pain or inflammatory disorders is also presented that includes administering an effective amount of the compound or its pharmaceutically acceptable salt or derivative, or mixtures thereof, to a host in need of analgesic anti-inflammatory therapy, optionally in a pharmaceutically acceptable carrier or diluent.(FR) Sont décrits des dérivés de 7-Azabicyclo[2.2.1]-heptane et -heptène à activité analgésique ou anti-inflammatoire qui peuvent être administrés à un mammifère, notamment l'homme, pour traiter la douleur et les troubles inflammatoires. Est également décrit un procédé pour traiter la douleur ou les troubles inflammatoires, consistant à administrer une dose efficace du composé ou de son sel ou dérivé pharmaceutiquement acceptable ou des mélanges de ceux-ci, à un hôte nécessitant une thérapie anti-inflammatoire analgésique, éventuellement dans un excipient ou un diluant pharmaceutiquement acceptable.

  disclose that can be administered to a mammal, including a human, to treat pain and inflammatory disorders. A method for the treatment of pain or inflammatory disorders is also presented that includes administering an effective amount of the compound or its pharmaceutically acceptable salt or derivative, or mixtures thereof, to a host in need of analgesic anti-inflammatory therapy, optionally in a pharmaceutically acceptable carrier or diluent.